Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements....

Descripción completa

Detalles Bibliográficos
Autores principales: Dalurzo, Mercedes L, Avilés-Salas, Alejandro, Soares, Fernando Augusto, Hou, Yingyong, Li, Yuan, Stroganova, Anna, Öz, Büge, Abdillah, Arif, Wan, Hui, Choi, Yoon-La
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420791/
https://www.ncbi.nlm.nih.gov/pubmed/34511936
http://dx.doi.org/10.2147/OTT.S313669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420791/
https://www.ncbi.nlm.nih.gov/pubmed/34511936
http://dx.doi.org/10.2147/OTT.S313669

Ejemplares similares